0 Reacties
0 aandelen
1K Views
0 voorbeeld
Zoeken
Ontdek nieuwe mensen, nieuwe verbindingen te maken en nieuwe vrienden maken
-
Please log in to like, share and comment!
-
Global Dual-Antibody ADC Market Growing at 6.2% CAGR Through 2032According to a new report from Intel Market Research, the global Dual-Antibody ADC market was valued at USD 477 million in 2024 and is projected to reach USD 691 million by 2032, exhibiting a steady CAGR of 6.2% during the forecast period (2025–2032). This growth is driven by increasing cancer prevalence and demand for precision medicine, superior tumor targeting capabilities of...0 Reacties 0 aandelen 624 Views 0 voorbeeld
-
HDAC Inhibitor Market Segmentation Analysis by Indication and End UserThe global HDAC inhibitor market is gaining significant momentum as the healthcare industry continues to advance targeted therapies for cancer and other complex diseases. Histone deacetylase (HDAC) inhibitors are a class of compounds that regulate gene expression by altering chromatin structure, making them valuable in the treatment of various malignancies and epigenetic disorders. The...0 Reacties 0 aandelen 982 Views 0 voorbeeld
-
Lymphoma Treatment Market Growth Potential Driven by Advances in Cancer TherapeuticsThe lymphoma treatment market is witnessing significant growth as healthcare providers increasingly focus on improving outcomes for patients diagnosed with Hodgkin lymphoma and non-Hodgkin lymphoma. Rising cancer prevalence, advancements in oncology research, and the growing adoption of innovative treatment approaches are contributing to the expansion of the market. The development of targeted...0 Reacties 0 aandelen 986 Views 0 voorbeeld
-
United States ADC for Solid Tumors Market Growing at 8.9% CAGR Through 2034The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...0 Reacties 0 aandelen 911 Views 0 voorbeeld